Fredun Pharmaceuticals announced July 16, 2026, as the record date for its 2:1 bonus equity share issue. Shareholders will receive two new shares for every one held, impacting EPS and share price.
Fredun Pharmaceuticals Announces Bonus Share Record Date
Fredun Pharmaceuticals Limited has fixed July 16, 2026, as the record date for its proposed 2:1 bonus equity share issue.
Reader Takeaway: 2:1 bonus issue proceeds; EPS dilution expected, share price adjustment on ex-date.
What just happened
Fredun Pharmaceuticals Limited has officially announced July 16, 2026, as the record date to determine eligibility for its bonus equity share issuance. This follows shareholder approval obtained at the Annual General Meeting held on June 30, 2026. The company will issue two fully paid-up equity shares for every one existing fully paid-up equity share held by shareholders.
Why this matters
For investors, the record date is a critical procedural step. It signifies that the company is moving forward with the bonus issue. While the total value of an investment remains the same, the bonus issue will increase the number of shares held, leading to a dilution of earnings per share (EPS) and an adjustment in the stock price on the ex-dividend date.
The backstory
The 2:1 bonus issue was approved by shareholders, and the company is now undertaking the necessary administrative steps to implement it. The company has also made provisions to adjust outstanding warrants to protect the economic interests of warrant holders, aligning with SEBI regulations.
What changes now
Shareholders who hold Fredun Pharmaceuticals stock before the close of trading on July 16, 2026, will be entitled to receive the bonus shares. The allotment of these new shares is scheduled for the working day following the record date (T+1), in line with SEBI circulars. The bonus shares will have the same face value of INR 10 and will rank equally with existing shares for future dividends and corporate actions.
Risks to watch
While a bonus issue is generally seen positively by the market as a sign of growth and confidence, investors should be aware of the potential dilution in EPS. The stock price typically adjusts downwards on the ex-date to reflect the increased number of shares outstanding.
Peer comparison
Bonus issues are a common corporate action in the Indian market. Many pharmaceutical companies periodically undertake such actions to reward shareholders and increase the liquidity of their stock. Specific peer comparisons are not directly relevant to this administrative announcement.
Context metrics (time-bound)
- Bonus Ratio: 2:1
- Record Date: July 16, 2026
- Deemed Date of Allotment: July 17, 2026 (T+1 from Record Date)
- Face Value: INR 10
What to track next
Investors should monitor the company's stock for the ex-date, which will be announced separately. They should also observe the credit of bonus shares to their demat accounts and the subsequent market performance of the stock.